NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC

This trial is testing a new first-line combination treatment for advanced pancreatic cancer (pancreatic ductal adenocarcinoma, PDAC) that has spread locally or to other organs. The combination includes nanoliposomal irinotecan plus oxaliplatin and capecitabine (NALIRI-XELOX) together with an immunotherapy drug called AK104. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of pancreatic ductal adenocarcinoma (PDAC) that is locally advanced or metastatic - You have not received any prior systemic treatment for this cancer - Your cancer has at least one measurable lesion - Your general health score (ECOG) is 0 or 1 - Your life expectancy is at least 3 months - Your organ function is adequate and you are not pregnant (with a negative test if applicable) **You may NOT be eligible if...** - You have untreated cancer in the brain or spinal cord covering (leptomeningeal metastasis) - You are currently on another clinical trial drug or have been recently - You have had major surgery within 4 weeks - You have received other anti-cancer treatment within 4 weeks Talk to your doctor to see if this trial is right for you.